Pediatric aerosol therapy: New devices and new drugs

Respiratory Care

Volumn 56, Issue 9, 2011, Pages 1411-1421

  Rubin, Bruce K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosol devices; Antibiotics; Children; Gene therapy; Medication adherence; Mucolytics; Nebulizers

Indexed keywords

ACETYLCYSTEINE; AMIKACIN; ANTIASTHMATIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; AZTREONAM; AZTREONAM LYSINE; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; DORNASE ALFA; ERGOTAMINE; EXPECTORANT AGENT; GENTAMICIN; GLUTATHIONE; HUMAN GROWTH HORMONE; ILOPROST; INSULIN; LEVOFLOXACIN; MORPHINE; MUCOLYTIC AGENT; NEW DRUG; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SURFACTANT; TIOTROPIUM BROMIDE; TOBRAMYCIN; UNINDEXED DRUG; UNIPROST; DRUG DERIVATIVE;

AEROSOL; AEROSOL DEVICE; AIRWAY; ANGINA PECTORIS; ARTICLE; ASTHMA; COUGHING; DEVICE; DISEASE EXACERBATION; DISPERSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG INACTIVATION; DRUG INDUCED HEADACHE; DYSPNEA; FIRST PASS EFFECT; GASTROINTESTINAL IRRITATION; HUMAN; INHALATION; LUNG; LUNG ALVEOLUS; LUNG CIRCULATION; LUNG DISEASE; MEDICAL NEBULIZER; METERED DOSE INHALER; MIGRAINE; NEPHROTOXICITY; ORGAN CIRCULATION; PERMEABILITY BARRIER; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SYSTEMIC THERAPY; TOPICAL TREATMENT; ARTIFICIAL VENTILATION; CHILD; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; REVIEW;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CHILD; EPOPROSTENOL; EQUIPMENT DESIGN; HUMANS; HYPERTENSION, PULMONARY; NEBULIZERS AND VAPORIZERS; RESPIRATION, ARTIFICIAL;

EID: 82255167120     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01246     Document Type: Article

References (56)

1. Wright BM. A new nebulizer. Lancet 1958;2(7036):24-25.
2. Freedman T. Medihaler therapy for bronchial asthma: a new type of aerosol therapy. Postgrad Med 1956;20(6):667-673.
3. Takizawa H. Recent development of drug delivery systems for the treatment of asthma and related disorders. Recent Pat Inflamm Allergy Drug Discov 2009;3(3):232-239.
4. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 2004;283(1-2):1-9.
5. Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005;18(3):273-282.
6. Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis 2008; 3(4):763-770.
7. van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or Handi Haler in COPD patients. Respir Med 2009;103(1):22-29.
8. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002;47(12):1406-1416; discussion 1416-1418.
9. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135(5):1223-1232.
10. Brand P, Friemel I, Meyer T, Schulz H, Heyder J, Häubetainger K. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci 2000;89(6):724-731.
11. Luisetti M, Kroneberg P, Suzuki T, Kadija Z, Muellinger B, Campo I, et al. Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer. Pulm Pharmacol Ther 2011;24(1):123-127.
12. Rubin BK. Bye-bye, blow-by (editorial). Respir Care 2007;52(8):981.
13. Amirav I, Balanov I, Gorenberg M, Groshar D, Luder AS. Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears! Arch Dis Child 2003;88(8):719-723.
14. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42(4):307-313.
15. Potter BP. Aerosol antibiotic therapy in suppurative diseases of the lung and bronchi. Dis Chest (now Chest) 1949;15(4):436-448.
16. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008;21(1):71-76.
17. Ring E, Eber E, Erwa W, Zach MS. Urinary N-acetyl-β-D-glucosaminidase activity in patients with cystic fibrosis on long term gentamicin inhalation Arch Dis Child 1998;78(6):540-543.
18. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams- Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30.
19. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7(4):265-271.
20. Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM. Acute, renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34(3):375-377.
21. MacIntyre N, Rubin BK. Should aerosolized antibiotics be administered to prevent or treat ventilator associated pneumonia in patients who do not have cystic fibrosis? Respir Care 2007;52(4):416-421; discussion 421-422.
22. Smith DJ, Bot S, Dellamary L, Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 2003;21(21-22):2805-2812.
23. Voynow JA, Rubin BK. Mucus, mucins, and sputum Chest 2009; 135(2):505-512.
24. Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respir Care 2007;52(7):859-865.
25. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365(9470):1552-1560.
26. Duijvestijn YC, Brand PL. Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatr 1999;88(1):38-41.
27. Henke M, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004;31(1):86-91.
28. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331(10):637-642.
29. Rubin BK, Kater AP, Goldstein AL. Thymosin ß4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. Chest 2006;130(5):1433-1440.
30. Rubin BK. Who will benefit from DNase? Pediatr Pulmonol 1999; 27(1):3-4.
31. Kishioka C, Okamoto K, Kim J-S, Rubin BK. Hyperosmolar solutions stimulate mucus secretion in the ferret trachea. Chest 2003; 124(1):306-313.
32. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354(3): 229-240.
33. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358(9290):1316-1321.
34. Wills PJ. Inhaled mannitol in cystic fibrosis. Expert Opin Investig Drugs 2007;16(7):1121-1126.
35. Fuloria M, Wu Y, Brandt ML, Rubin BK. Effect of meconium on the surface properties of perflubron. Pediatr Crit Care Med 2004;5(2): 167-171.
36. Murgia X, Gastiasoro E, Mielgo V, Alvarez-Diaz F, Lafuente H, Valls-i-Soler A, et al. Surfactant and perfluorocarbon aerosolization by means of inhalation catheters for the treatment of respiratory distress syndrome: an in vitro study. J Aerosol Med Pulm Drug Deliv 2011;24(2):81-87.
37. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis. A prospective randomized controlled trial. JAMA 1997; 278(17):1426-1431.
38. Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, Meyer T. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009; 34(2):354-360.
39. Snyder AH, McPherson ME, Hunt JF, Johnson M, Stamler JS, Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 2002;165(7):922-926.
40. Eckstein JW, Fung J. A new class of cyclosporin analogues for the treatment of asthma. Expert Opin Invest. Drugs 2003;12(4):647-653.
41. Groves S, Galazka M, Johnson B, Corcoran T, Verceles A, Britt E, et al. Inhaled cyclosporine and pulmonary function in lung transplant recipients. J Aerosol Med Pulm Drug Deliv 2010;23(1):31-39.
42. Rubin BK. Experimental macromolecular aerosol therapy. Respir Care 2000;45(6):684-694.
43. Gonda I. Systemic delivery of drugs to humans via inhalation. J Aerosol Med 2006;19(1):47-53.
44. Gaensslen M. Über inhalation von insulin. Klin Wochenschr 1925; 4(2):71-72. Article in German.
45. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005;50(9):1161-1174; discussion 1174-1176.
46. Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv 2008;21(1): 1-12.
47. Armer TA, Shrewsbury SB, Newman SP, Pitcairn G, Ramadan N. Aerosol delivery of ergotamine tartrate via a breath-synchronized plumecontrol inhaler in humans. Curr Med Res Opin 2007;23(12):3177-3187.
48. Foral PA, Malesker MA, Huerta G, Hilleman DE. Nebulized opioids use in COPD. Chest 2004;125(2):691-694.
49. Panitch HB, Keklikian EN, Motley RA, Wolfson MR, Schidlow DV. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol 1990;9(3):170-176.
50. Rubin BK, Pohanka V. Beyond the guidelines: fatal and near-fatal asthma. Paediatr Respir Rev 2011 (in press).
51. Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care 2010;55(7):845-851.
52. Bhashyam AR, Wolf MT, Marcinkowski AL, Saville A, Thomas K, Carcillo JA, Corcoran TE. Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv 2008;21(2):181-188.
53. Longest PW, Tian G, Hindle M. Improving the lung delivery of nasally administered aerosols during noninvasive ventilation: an application of enhanced condensational growth (ECG). J Aerosol Med Pulm Drug Deliv 2011;24(2):103-118.
54. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidencebased guidelines. Chest 2005;127(1):335-371.
55. Rubin BK. What does it mean when a patient says, "My asthma medication isn't working?". Chest 2004;126(3):972-981.
56. Rubin BK. Adherence to asthma therapy: the "blocked receptor". Pediatr Pulmonol 2004;26(Suppl):36-37.